| Literature DB >> 22426528 |
Ali A El-Emam1, Khalid A Alrashood, Mohamed A Al-Omar, Abdul-Malek S Al-Tamimi.
Abstract
The reaction of adamantane-1-carbohydrazide (1) with heterocyclic aldehydes, namely 5-(4-chlorophenyl)isoxazole-3-carboxaldehyde (2a), 5-(4-methylphenyl)isoxazole-3-carboxaldehyde (2b), 5-(4-methoxyphenyl)isoxazole-3-carboxaldehyde (2c), 1H-imidazole-2-carboxaldehyde and 2-butyl-4-chloro-1H-imidazole-5-carboxaldehyde, in ethanol, yielded the corresponding N'-heteroarylidene-1-adamantylcarbohydrazides 3a, 3b, 3c, 4 and 5, respectively, in good yields. The 4-acetyl-1,3,4-oxadiazoline analogues 6a‑c were prepared in 48-55% yields by heating their corresponding N'-heteroarylidene-1-adamantylcarbohydrazides 3a-c with acetic anhydride for two hours. Compounds 3a-c, 4, 5 and 6a-c were tested for in vitro activities against a panel of Gram-positive and Gram-negative bacteria and the yeast-like pathogenic fungus Candida albicans. Compounds 4 and 5 displayed potent broad-spectrum antimicrobial activity, while compounds 3a-c showed good activity against the Gram-positive bacteria.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22426528 PMCID: PMC6268319 DOI: 10.3390/molecules17033475
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of compounds 3a–c, 4, 5 and 6a–c.
Antimicrobial activity of compounds 3a–c, 4, 5 and 6a–c (200 µg/8 mm disc), the broad spectrum antibacterial antibiotics gentamicin (100 µg/8 mm disc), ampicillin (100 µg/8 mm disc) and the antifungal drug clotrimazole (100 µg/8 mm disc) against Staphylococcus aureus IFO 3060 (SA), Bacillus subtilis IFO 3007 (BS), Micrococcus luteus IFO 3232 (ML), Escherichia coli IFO 3301(EC), Pseudomonas aeuroginosa IFO 3448 (PA), and Candida albicans IFO 0583 (CA).
| Comp. No. | Clog
| Diameter of Growth Inhibition Zone (mm) * | |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| 4.96 | 19(16) † | 22(8) † | 17 | 11 | - | - | |
| 4.74 | 18(16) † | 18(16) † | 14 | - | - | - | |
| 4.24 | 17 | 18(16) † | 13 | - | - | - | |
| 2.30 | 32(0.5) † | 26(0.5) † | 23(8) † | 16 | 11 | 17 | |
| 3.89 | 28(1) † | 30(1) † | 22(4) † | 19(8) † | 14 | 16 | |
| 5.20 | 12 | 11 | 11 | - | - | - | |
| 4.95 | - | - | - | - | - | - | |
| 4.48 | - | - | - | - | - | - | |
| 26(2) † | 25(2) † | 18(2) † | 20(0.5) † | 19(1) † | NT | ||
| 23(2) † | 21(0.5) † | 19(2) † | 17(2) † | 16(2) † | NT | ||
| NT | NT | NT | NT | NT | 21 | ||
* (-): Inactive (inhibition zone ≤ 10 mm); (NT): Not tested; † The figures shown in parentheses represent the MIC values (µg/mL).